CVM-005: A multicentre, single-arm, phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in patients with treatment-refractory advanced neuroendocrine tumours (NET)

#4372

Introduction: NETs are highly vascularised tumours and a viable target for anti-VM therapies. CVM-1118 is an anti-tumour agent with multiple MOAs, including disruption of VM networks and induction of apoptosis via targeting mitochondrial TRAP1 protein.

Aim(s): To study CVM-1118’s activity in advanced NET patients (pts).

Materials and methods: Pts. of low to intermediate grade (G1–G2) NETs of lung, GI tract or pancreas refractory to SOC therapy and progressed within 6 months prior to screening received oral CVM-1118 at 200–300 mg BID in 28-day cycles. Prespecified primary endpoint: PFS. Secondary endpoints: ORR, OS, safety.

Conference:

Presenting Author: Yen C

Authors: Yen C, Chen M, Chen Y, Bai L, Chen J,

Keywords: CVM-1118, GEP-NET, anti-vasculogenic mimicry,